Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05382793
Other study ID # BASEC2022-00130
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 16, 2022
Est. completion date July 2024

Study information

Verified date May 2022
Source University Children's Hospital, Zurich
Contact Maria Andersson, Dr. sc.
Phone +41442668462
Email maria.andersson@kispi.uzh.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Human milk is the only source of iodine during early infancy and adequate iodine intake during lactation is necessary to assure optimal thyroid function in breastfed infants. However, the physiological requirement of iodine in lactating women is uncertain and recommendations for the daily dietary average requirement are poorly defined. WHO recommends iodine supplementation to lactating women in populations with incomplete coverage of iodized salt and deficient iodine intake, but the scientific evidence is weak and the optimal dose is uncertain. The primary objective is to assess the daily dietary average requirement for iodine in lactating women. Secondary objectives are to: - Estimate the daily average requirement for iodine in exclusively breastfed infants; - Assess the dose-response of dietary iodine supplements on breast milk iodine concentration in lactating women with adequate and inadequate habitual iodine intakes; - Estimate the maternal iodine intake required to provide exclusively breastfed infants with an adequate iodine intake via breast milk.


Description:

This study is a single center, randomized, controlled, dose-response metabolic balance study with cross-over design. The study will be conducted in 24 exclusively breastfeeding women and their infants receding in Zürich, Switzerland. The study involves an initial screening, a 2 weeks run-in period and a balance period over 3 weeks. Participating women will be allocated to two groups based on their consumption of dietary iodine supplements during pregnancy. Women who consumed daily iodine supplements during pregnancy will be assigned to group 1 (n=12) and receive daily supplements containing 150 µg iodine for 2 weeks, whereas women who did not will be enrolled in group 2 and will receive no supplement during the run-in period. Breast milk and spot urine samples (mothers and infants) will be collected daily in all participants during two weeks for the measurement of breast milk and urinary iodine concentrations. During the balance period, all women will receive either no supplement, iodine supplements providing 150 µg/day, or 300 µg/day in random order with cross-over design. Each supplement dose will be assessed in a test period of 7 days, including 2 run-in days, 3 balance days and 2 wash-out days. The supplements will be consumed during the first 5 days in each test-period. During the 3 balance days, the daily iodine intake and excretion will be measured in mothers and infants, and the iodine retention will be calculated for each regimen and study group. The minimum daily average requirement will be determined as the iodine intake where the iodine retention is zero.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date July 2024
Est. primary completion date November 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 49 Years
Eligibility Mother-infant pairs in good health, free of any acute illness or chronic thyroid disease. Mothers Inclusion criteria: 1. Consent to enroll herself and her baby; 2. Age 18 to 49 years; 3. Singleton pregnancy; 4. Exclusively breastfeeding; 5. Self-estimated BMI <30 kg/m2 before conception. Exclusion criteria: 1. TSH >6 mIU/L; 2. Anemia (Hb <11.7 g/L); 3. Pregnancy (self-reported); 4. Acute illness (e.g. gastroenteritis); 5. History of thyroid disease, diabetes, metabolic disease or inflammatory bowel disease (self-reported); 6. Currently smoking (>1 cigarette/day); 7. Drug abuse or extensive alcohol intake; 8. Exposure to iodine-containing X-ray or computed tomography contrast agents during the past 6 months; 9. Adenomatous goiter, dermatitis, anti-C1q-vasculitis. Infants Inclusion criteria: 1. Full term (38-42 weeks); 2. Birthweight =2.5 kg; 3. Exclusively breastfed; 4. Age 0-10 weeks at recruitment. Exclusion criteria: 1. Age >6 months; 2. TSH >10 mIU/L at neonatal screening at 2-5 days after birth (i.e. infants not requested to attend recall assessment); 3. Diagnosed or suspected colic.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Control
No iodine
Iodide (150 µg/day)
A single oral tablet once daily for five days providing 150 µg iodine as potassium iodide
Iodine (300 µg/day)
Two oral tablets (150 µg + 150 µg) daily for five days providing 300 µg iodine as potassium iodide

Locations

Country Name City State
Switzerland Nutrition Research Unit, University Children's Hospital Zurich Zürich

Sponsors (2)

Lead Sponsor Collaborator
University Children's Hospital, Zurich ETH Zurich (Switzerland)

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal iodine retention (µg/day) Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day) 24 hours
Secondary Maternal iodine excretion in breast milk (µg/day) Estimated from measured breast milk iodine concentration (µg/L) and breast milk volume (L) 24 hours
Secondary Infant iodine retention (µg/day) Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day) 24 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1